Modulating kidney transplant interstitial fibrosis and tubular atrophy: Is the RAAS an important target?

Kidney International

Volumn 85, Issue 2, 2014, Pages 240-243

  Amer, Hatem ^a   Griffin, Matthew D ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; RENIN;

ALDOSTERONE BLOOD LEVEL; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; LOSARTAN; MALE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84893312585     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.400     Document Type: Note

References (13)

1. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
2. Stegall MD, Park WD, Larson TS et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707
3. Amer H, Lieske JC, Rule AD et al. Urine high and low molecular weight proteins one-year post-kidney transplant: Relationship to histology and graft survival. Am J Transplant 2013; 13: 676-684
4. Park WD, Griffin MD, Cornell LD et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997
5. Morath C, Schmied B, Mehrabi A et al. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation. Clin Transplant 2009; 23(Suppl 21): 33-36
6. Hiremath S, Fergusson D, Doucette S et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350-2360
7. Opelz G, Dohler B. Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: A collaborative transplant study report. Am J Transplant 2011; 11: 2483-2489
8. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899
9. Ibrahim HN, Jackson S, Connaire J et al. Angiotensin II blockade in kidney transplant recipients. J AmSoc Nephrol 2013; 24: 320-327
10. Issa N, Ortiz F, Reule SA et al. The renin-Aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney Int 2014; 85: 404-415
11. Beckerhoff R, Uhlschmid E, Vetter W et al. Plasma renin and aldosterone after renal transplantation. Kidney Int 1974; 5: 39-46
12. Wolf G. Renal injury due to renin-Angiotensinaldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006; 70: 1914-1919
13. LeBleu VS, Taduri G, O'Connell J et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013; 19: 1047-1053